A product for removing chylomicrons from in vitro blood samples and its application

By grafting heparin onto the surface of silica aerogel and combining it with a specific drying process, heparinized silica-based composite aerogels were prepared, solving the problems of preparing high-performance aerogels and pretreatment of lipemia samples under normal pressure. This achieved efficient, convenient, and low-cost removal of chylomicrons and capture of biomolecules.

CN123102305APending Publication Date: 2026-11-17QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES) +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611251621.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-02
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to prepare silica aerogels with both high specific surface area and specific adsorption function under normal pressure drying conditions. Furthermore, existing methods for pretreatment of lipemia samples suffer from high cost, complex operation, high destructiveness, or low efficiency, making them unsuitable for widespread use in clinical laboratories.

Method used

A heparinized silica-based composite aerogel was prepared by grafting heparin molecules onto the surface of silica aerogel under normal pressure, combined with an acid-base catalytic method and a gradient drying process. This resulted in an aerogel material with high specific surface area, suitable pore size and density, which was then specifically adsorbed by utilizing the bioaffinity of heparin.

Benefits of technology

A high-performance silica aerogel was prepared under normal pressure, which can efficiently, conveniently and cost-effectively remove chylomicrons from blood samples while maintaining the accuracy of other detection indicators. It is suitable for the fields of bioseparation, affinity purification and anticoagulant materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123102305A_ABST
    Figure CN123102305A_ABST
Patent Text Reader

Abstract

This invention provides a product for removing chylomicrons from in vitro blood samples and its applications, belonging to the field of functional nanoporous materials technology. Heparinized silica-based composite aerogels were successfully prepared under normal pressure drying conditions, simultaneously maintaining the nanoporous structure of the silica aerogel and effectively modifying its surface bioactive functional groups. The resulting composite aerogel material possesses extremely high specific surface area, suitable mesopore size, and suitable density; these three factors synergistically endow the material with ultra-high oil absorption performance. Furthermore, heparin modification provides strong affinity sites for the composite aerogel, enabling specific adsorption using the bioaffinity of heparin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention is a divisional application of application number 202610979187.7, application date 2026.07.02, entitled "A heparinized silica-based composite aerogel and its preparation method and application". Technical Field

[0002] This invention relates to the field of functional nanoporous materials technology, specifically a product for removing chylomicrons from in vitro blood samples and its application. Background Technology

[0003] Silica aerogels, due to their extremely high specific surface area and abundant porous structure, have wide applications in adsorption, catalysis, and thermal insulation. Traditional methods for preparing high-performance silica aerogels often employ supercritical drying technology to avoid the collapse of the nanoporous structure caused by capillary forces during the drying process. However, supercritical drying equipment is expensive, the process is complex, and energy consumption is high, severely restricting the large-scale production of silica aerogels and their application in cost-sensitive fields.

[0004] In recent years, researchers have attempted to prepare silica aerogels using atmospheric pressure drying methods. However, for applications requiring materials to possess specific biocompatibility, how to simultaneously maintain the nanoporous structure of silica aerogels and effectively modify surface bioactive functional groups (such as heparin) under atmospheric pressure drying remains an unsolved technical challenge.

[0005] Heparin is a highly sulfated acidic mucopolysaccharide with densely distributed sulfonic acid groups (-SO3H) and carboxyl groups (-COOH) on its molecular chain, exhibiting strong negative charge in aqueous solution. Based on this property, heparin can specifically adsorb various positively charged bioactive molecules through electrostatic interactions, hydrogen bonding, and conformational recognition mechanisms. These include antithrombin III (AT-III), coagulation factors (such as FIX and FXI), various growth factors (such as basic fibroblast growth factor bFGF and vascular endothelial growth factor VEGF), viral particles (such as adenovirus and HPV), interferon, nucleic acid-binding proteins, and certain cationic drugs. Therefore, heparin-modified solid matrices have broad application prospects in fields such as bioseparation, affinity purification, drug delivery, and anticoagulant materials. This invention aims to utilize this bioaffinity property of heparin by grafting heparin molecules onto the surface of silica aerogel, constructing a novel composite aerogel material that can be prepared under normal pressure drying conditions and possesses both high specific surface area and specific adsorption function.

[0006] Patent publication number CN 114394600 A discloses a hydrophobic and oleophilic flexible silica aerogel, the product being a hydrophobic aerogel powder, primarily for thermal insulation applications. Patent publication number CN 113461020 A discloses a flexible hydrophobic bulk silica aerogel; the aerogel particles have methylated surfaces, exhibiting low density, low thermal conductivity, and good hydrophobicity, and the product is also a hydrophobic powder. Although both patents prepare silica aerogels under normal pressure drying conditions, the resulting aerogels are hydrophobic. Their hydrophobic surfaces not only fail to immobilize hydrophilic biomolecules such as heparin but also repel target adsorbates in aqueous media.

[0007] Chylomicrons are the largest lipoprotein particles in blood, with triglycerides at their core and an outer layer of apolipoproteins, phospholipids, and a small amount of cholesterol. In clinical laboratory testing, the quality of the blood sample is crucial for accurate results. Blood samples from patients with hyperlipidemia or collected after meals often appear chylous and cloudy due to high concentrations of chylomicrons. These particles cause light scattering, severely interfering with analytical methods that rely on absorbance, turbidity, or fluorescence measurements, leading to falsely elevated or decreased test results. This is a significant potential source of misdiagnosis and missed diagnosis in clinical practice. Statistics show that varying degrees of chylous interference exist in clinical samples, with higher levels of interference in specific populations or time periods.

[0008] To eliminate chylous interference, various sample pretreatment methods have been developed, but all have significant limitations. For example, physical dilution uses physiological saline or specific buffer solutions to dilute the sample. While simple and low-cost, this method only reduces the concentration of interfering substances, not eliminating them. It also proportionally dilutes the analyte, potentially lowering low concentrations below the detection limit, thus not improving the signal-to-noise ratio and resulting in a high error rate. Organic solvent extraction uses organic solvents such as ether and hexane to extract lipids. This method is effective in removing some lipids, but the process is cumbersome and time-consuming. Furthermore, organic solvents can easily denature and inactivate proteins and may introduce volatile toxic reagents, posing safety risks. Therapeutic methods have been gradually phased out in clinical laboratories. Ultracentrifugation uses low-temperature ultracentrifugation (e.g., >100,000×g) to separate lipoproteins by density difference. This method is relatively effective, but it heavily relies on expensive high-speed refrigerated centrifugation equipment, has a long processing time (60-90 minutes), and the high-speed shear force may cause hemolysis, affecting red blood cell-related indicators, making it difficult to popularize in routine laboratories, especially in primary healthcare institutions. Solid-phase affinity adsorption uses chromatographic materials based on specific ligands (e.g., antibodies, small molecules) to selectively adsorb lipoproteins. Representative products include Thermo LipidClear. This method has a high clearance efficiency (>90%), but it is extremely expensive (costing tens of RMB per test), the operation process is complex and time-consuming (often requiring more than 2 hours), and the adsorption medium may non-specifically adsorb key proteins such as fibrinogen, affecting coagulation function testing.

[0009] In recent years, although there have been research reports based on novel materials (such as functionalized magnetic particles and microfluidic chips), such as Cellix's (Ireland) Lipochip microfluidic device, attempting to achieve rapid and efficient lipid removal, these technologies are either still in the laboratory research stage, with complex processes and poor reproducibility, or cannot be applied on a large scale in clinical practice due to high manufacturing costs or the need for specialized equipment. Currently, in the pretreatment of lipemia samples, the high-end market is monopolized by expensive imported solid-phase adsorption products, while primary care facilities rely heavily on traditional methods with high error rates or significant destructive potential.

[0010] In summary, there is an urgent need in current clinical practice for a lipid-based blood sample pretreatment solution that can balance high efficiency, high fidelity, speed and convenience, low cost and universality. Summary of the Invention

[0011] To address the shortcomings of existing technologies, this invention provides a heparinized silica-based composite aerogel and its preparation method.

[0012] The technical solution of this invention is as follows: A heparinized silica-based composite aerogel, wherein heparin molecules are grafted onto the surface of the composite aerogel, and the specific surface area is 700-800 m². 2 / g, pore size 10~50nm, particle size 20~50μm, density 1.19~1.21g / cm³ 3 It has an oil absorption value of 200~300mL / g and a Zeta potential of -10~-20mV.

[0013] The preparation method of the above-mentioned heparinized silica-based composite aerogel includes the following steps: (1) Mix alkoxysilane precursor, water and alcohol solvent, then use an acid catalyst to adjust the pH of the system to 3~5, stir at 20~50℃ for 0.5~4h to carry out catalytic hydrolysis, and obtain silica sol; (2) Add an alkaline catalyst to the silica sol in step (1) to adjust the pH of the system to 8-10, stir evenly and let stand so that it gels within 10-60 min, and then age at 40-70℃ for 6-48 h to obtain wet gel. (3) Immerse the wet gel from step (2) in an ethanol solution containing sodium heparin and silane coupling agent, and react at 30~60℃ for 12~72h under sealed conditions to obtain the modified gel. (4) The modified gel in step (3) is rinsed with anhydrous ethanol 2 to 3 times to remove unreacted heparin sodium, free silane coupling agent and byproducts. Then it is immersed in a variety of low surface tension solvents for displacement, each displacement for 6 to 12 hours. Then it is dried under gradient atmospheric pressure and ground to obtain heparinized silica-based composite aerogel.

[0014] Preferably, the alkoxysilane precursor in step (1) is tetraethyl orthosilicate.

[0015] Preferably, the alcohol solvent in step (1) is ethanol.

[0016] Preferably, the acid catalyst in step (1) is one of hydrochloric acid, acetic acid, and citric acid.

[0017] Preferably, the mass ratio of the alkoxysilane precursor, water, and alcohol solvent in step (1) is 3:1:3.

[0018] Preferably, the alkaline catalyst in step (2) is ammonia or an organic amine.

[0019] Preferably, the silane coupling agent in step (3) is 3-aminopropyltriethoxysilane (APTES) or 3-glycidyl etheroxypropyltrimethoxysilane (GPTMS).

[0020] Preferably, the volume ratio of ethanol in the ethanol solution in step (3) is 96%~98%.

[0021] Preferably, the volume of the ethanol solution in step (3) is 3 to 5 times the volume of the wet gel, so as to ensure that the aqueous phase and reaction byproducts in the internal pores of the wet gel can diffuse and be replaced to the outside.

[0022] Preferably, the concentration of sodium heparin in the ethanol solution in step (3) is 0.1~5 mg / mL, and the concentration of silane coupling agent is 1~50 mg / mL.

[0023] Preferably, the low surface tension solvents in step (4) are ethanol, acetone, and n-hexane in sequence.

[0024] Preferably, the gradient atmospheric pressure drying in step (4) includes: first stage: drying at 20~30℃ and relative humidity of 50%~70% for 12~36 h; second stage: drying at 30~40℃ and relative humidity of 30%~50% for 12~36 h; third stage: drying at 40~60℃ and relative humidity of <30% to constant weight.

[0025] The application of the above-mentioned heparinized silica-based composite aerogel in the removal of chylomicrons from in vitro blood samples.

[0026] A product for removing chylomicrons from in vitro blood samples, comprising a silica-based composite aerogel.

[0027] Preferably, the product is a reagent kit.

[0028] Preferably, the silica-based composite aerogel is a heparinized silica-based composite aerogel, and the surface of the composite aerogel is grafted with heparin molecules.

[0029] Preferably, the heparinized silica-based composite aerogel has a particle size of 20-50 μm, an oil absorption value of 200-300 mL / g, and a density of 1.19-1.21 g / cm³. 3 .

[0030] More preferably, the heparinized silica-based composite aerogel is prepared according to the above preparation method.

[0031] The above-mentioned products are used to remove chylomicrons from in vitro blood samples.

[0032] Preferably, the application method is as follows: mix silica-based composite aerogel with the blood sample to be treated at a mass-to-volume ratio of 100~300 (mg): 1 (mL), shake at room temperature for 1~5 min, then centrifuge at 3000~4000 r / min for 8~12 min, and take the supernatant for subsequent detection.

[0033] Preferably, the blood sample is serum or plasma.

[0034] Beneficial effects: (1) This invention breaks away from the conventional two-step substitution-grafting method for silane coupling agent modification, and creatively combines the two key steps of solvent substitution and surface heparinization grafting, achieving a high degree of synergy between structural protection and functionalization. Conventional silane coupling agent modification is mostly carried out in anhydrous organic solvents such as toluene, while this invention is carried out in a high-concentration (97%) ethanol solution. Ethanol is both a substitution solvent and a reaction medium, and heparin, a large molecular polysaccharide, is also present, making the reaction conditions extremely special. In addition, in the high-concentration ethanol medium, heparin, as a strongly hydrophilic polysaccharide, can be efficiently and stably grafted onto the gel surface with the coupling agent and withstand the test of subsequent gradient drying, achieving good grafting effect and firmness, which is hard for technicians to predict. In summary, this invention utilizes a silane coupling agent to simultaneously react with heparin molecules and silanol groups on the gel surface during solvent replacement, thereby maintaining the nanoporous structure of silica aerogel and effectively modifying the surface bioactive functional groups. Heparinized silica-based composite aerogels were successfully prepared under normal pressure drying conditions, showing broad application prospects in fields such as bioseparation, affinity purification, drug delivery, and anticoagulant materials.

[0035] The mechanism by which heparin is successfully modified on the surface of silica aerogel may be as follows: In an ethanol solution containing sodium heparin and a silane coupling agent, ethanol first gradually displaces water, unreacted small molecule alcohols, and hydrolysis byproducts from the wet gel channels, reducing the surface tension within the pores and laying the foundation for subsequent atmospheric pressure drying. At the same time, the silane coupling agent dissolved in the alcohol phase diffuses into the surface of the gel skeleton, and its alkoxy groups (such as ethoxy groups) undergo a condensation reaction with the silanol groups (Si-OH) on the silica skeleton surface to form covalent bonds, thereby introducing amino or epoxy groups into the gel surface. The abundant carboxyl groups (-COOH) or sulfonic acid groups (-SO3H) on the sodium heparin molecular chain undergo amidation or ionic complexation with the amino groups (-NH2) at the end of the coupling agent in the alcohol phase under heating conditions, ultimately firmly grafting heparin molecules onto the surface of the aerogel channels in the form of covalent bonds or highly stable electrostatic complexes.

[0036] (2) Synergistic atmospheric pressure drying process of “skeleton strengthening” and “capillary force cancellation”: Through a two-step catalytic method of acid first and then alkali, a wet gel network with higher cross-linking degree and stronger skeleton is formed, which can better resist drying stress; then, the precise gradient drying process slowly reduces the ambient humidity, so that the solvent evaporates gently, minimizing the damage of capillary force to the nanoporous structure.

[0037] (3) The composite aerogel material obtained by this invention has an extremely high specific surface area (759.5759 m²). 2Suitable mesopore size (10~50nm) and suitable density (1.19~1.21g / cm³) 3 The synergistic effect of these three factors endows the material with extremely high oil absorption capacity, with an oil absorption value approximately 100 to 500 times that of conventional activated carbon. Furthermore, heparin modification provides the composite aerogel with strong affinity sites, allowing it to achieve specific adsorption using heparin's bioaffinity. Therefore, when processing chylomicrons in blood samples, this composite aerogel material can efficiently remove oily impurities through physical adsorption while simultaneously utilizing the bioaffinity of heparin to specifically capture target biomolecules. The specific affinity mechanism may involve molecular recognition between heparin and specific domains on apolipoproteins, enabling the composite aerogel material to achieve near-complete chyle removal in a very short time without interfering with other detection indicators. This highly efficient, convenient, and low-cost approach solves a long-standing technical challenge in current clinical testing. Attached Figure Description

[0038] Figure 1 Photographs showing the appearance of the composite aerogel; Figure 2 SEM scan image of the composite aerogel; Figure 3 The blood sample was turbid and chylous. Figure 4 The sample of chylolipemia after treatment with composite aerogel; Figure 5 The chylolipemia sample was treated with unheparinized silica aerogel. Detailed Implementation

[0039] The present invention will now be described in detail with reference to specific embodiments. The description in this section is merely illustrative and explanatory, and should not be construed as limiting the scope of protection of the present invention.

[0040] Explanation of the source of experimental materials: Tetraethyl orthosilicate: CAS number 562-90-3; Heparin sodium: CAS number 9041-08-1; 3-Aminopropyltriethoxysilane: CAS No. 919-30-2.

[0041] Chylolipemic Sample: The chylolipemic sample used in this example was an artificial sample, prepared according to the standard for severely chylous blood. The specific preparation method is as follows: Physiological saline was used as the base solution, and 10%–20% (v / v) fetal bovine serum (FBS) was added, along with triglycerides to a final concentration of 20–35 mmol / L. Simultaneously, total cholesterol was supplemented to 10–20 mmol / L, phospholipids to 5–15 mmol / L, and appropriate amounts of albumin and globulin were added (to maintain the total protein content at 60–80 g / L). The mixture was then ultrasonically emulsified or vortexed to form a stable, turbid chylous liquid. An absorbance greater than 0.5 at 600 nm using a UV-Vis spectrophotometer confirmed that the sample had reached a severely chylous state. This chylolipemic sample simulates the lipid composition and physical properties of clinically diagnosed severely lipemic samples and can be used to evaluate the adsorption performance of composite aerogels.

[0042] Example 1: Preparation of heparinized silica-based composite aerogel (1) Acid-catalyzed hydrolysis and preliminary polycondensation: Tetraethyl orthosilicate, water and ethanol were mixed in a mass ratio of 3:1:3, and then the pH of the system was adjusted to 4.0 with hydrochloric acid. The mixture was stirred at 35°C for 2 hours to carry out catalytic hydrolysis and obtain clear silica sol.

[0043] (2) Alkali-catalyzed gelation and aging: Add ammonia to the silica sol in step (1) to adjust the pH of the system to 9.2, stir quickly and evenly, and let stand for 35 minutes to gel; then age at 65°C for 26 hours to obtain a wet gel with initial strength.

[0044] (3) Simultaneous solvent replacement and surface modification: The wet gel from step (2) was immersed in a 97% ethanol solution containing 2 mg / mL heparin sodium and 5 mg / mL 3-aminopropyltriethoxysilane. The volume of the ethanol solution was 5 times the volume of the wet gel. The reaction was carried out at 40°C for 48 h under sealed conditions. During the reaction, the container was gently shaken every 6 to 12 h to ensure that the solution was in full contact with the gel surface. The modified gel was obtained.

[0045] (4) Gradient atmospheric pressure drying: The modified gel in step (3) was rinsed twice with anhydrous ethanol to remove unreacted heparin sodium, free silane coupling agent and byproducts. Then it was immersed in ethanol, acetone and n-hexane in sequence for final replacement, each replacement for 8 hours. The gel was then placed in an atmospheric pressure drying oven with programmable temperature and humidity control and dried according to the following gradient: 25℃ and 60% relative humidity for 24 hours; 35℃ and 40% relative humidity for 24 hours; 45℃ and <20% relative humidity for constant weight. The gel was then ground to obtain heparinized silica-based composite aerogel, hereinafter referred to as "composite aerogel".

[0046] Example 2: Appearance of composite aerogel The composite aerogel prepared in Example 1 was observed and photographed under normal temperature and pressure conditions using a digital camera. The photographic results are as follows: Figure 1 As shown. By Figure 1 As can be seen, the aerogel prepared by this invention is white in appearance, fluffy in texture, and has a typical aerogel texture, feeling similar to fine, soft powder with no obvious granular feel. Referring to the density determination method in GB / T 34336-2017, the density of the composite aerogel was tested using the volume-mass method, and the result was 1.21 g / cm³. 3 .

[0047] Example 3: Microstructure of composite aerogel The composite aerogel prepared in Example 1 was scanned using a scanning electron microscope (SEM), and the results are as follows: Figure 2 As shown. By Figure 2 As can be seen, the aerogel prepared by this invention consists of microparticles composed of a nano-network structure. The nanoscale fibers or particles are interconnected to form abundant and interconnected pores, which is a typical characteristic of "aerogel". The pores in the image are very abundant and uniform, indicating that the composite aerogel has a high porosity, which provides a huge internal space and channels for subsequent adsorption. In addition, the composite aerogel network structure in the image is continuous and the skeleton is clear, which reflects that it has maintained a good structure during the preparation and drying process and has not undergone serious collapse. This is also the basis for achieving a high specific surface area.

[0048] Example 4: Properties of Composite Aerogels The specific surface area, pore size, particle size, zeta potential, and oil absorption value of the composite aerogel prepared in Example 1 were measured. Among them: The specific surface area was measured using the BET multi-point method.

[0049] The aperture was measured using the BJH method.

[0050] The particle size was determined using a Hydro 2000SM (A) wet laser particle size analyzer with ethanol as the dispersant.

[0051] The method for detecting zeta potential is as follows: the zeta potential of the composite aerogel is detected using a zeta potential analyzer, and water is used as the dispersant.

[0052] The oil absorption value was tested by referring to the oil absorption value determination method in the national standard GB / T 3780.2—2017.

[0053] The test results for specific surface area, pore size, particle size, Zeta potential, and oil absorption value are shown in Table 1. Table 1. Summary of Test Results

[0054] Table 1 shows several key properties of the composite aerogel obtained in this invention. From Table 1, we can obtain: The specific surface area is 759.5759 m². 2 / g, which is an extremely high value, far exceeding the specific surface area of ​​ordinary activated carbon, reaching the level of high-performance aerogels. This directly confirms the extremely porous structure seen in the SEM electron microscope images above. The huge specific surface area means that the composite aerogel has a massive number of potential adsorption sites.

[0055] With a pore size of 10~50nm, it not only provides a large specific surface area and active sites, but also provides a convenient channel for molecule loading and transport.

[0056] With a particle size of 20~50μm, the uniform particle size distribution ensures the stability of the product, and the smaller particle size also provides more active sites for molecular loading and transport.

[0057] The zeta potential is -19.6 mV, indicating negative charge. This is a key indicator for predicting its interaction with charged particles and direct evidence of successful heparin modification: heparin is a strongly negatively charged polysaccharide; if heparin is successfully grafted onto the surface of the composite aerogel, its zeta potential should exhibit strong negative charge. The zeta potential of ungrafted ordinary silica aerogel was measured to be -8.87 mV.

[0058] The preparation method of ordinary silica aerogel without heparin grafting is different from that in Example 1. The wet gel in step (2) is directly subjected to gradient atmospheric pressure drying in step (4), that is, step (3) is omitted.

[0059] With an oil absorption value of 265 mL / g, it is at the forefront of the adsorption material field, approximately 100 to 500 times that of conventional activated carbon. This ultra-high oil absorption performance is attributed to the material's extremely high specific surface area (759.5759 m²). 2 Suitable mesopore size (10~50nm) and suitable density (1.19~1.21g / cm³) 3 The high oil absorption value gives the material significant advantages in oil spill cleanup and oily wastewater treatment. When treating biological samples containing oily components, it can efficiently remove oily impurities through physical adsorption, while using the electrostatic binding and bioaffinity of heparin to specifically capture target biomolecules, achieving one-step processing and dual functions.

[0060] Example 5: Aqueous Phase Stability of Composite Aerogels The composite aerogel prepared in Example 1 was immersed in PBS buffer at pH 7.4 for 24 h, and the shedding rate of heparin functional groups in the composite aerogel was detected. The results showed that the shedding rate of heparin functional groups was less than 5%, and the composite aerogel structure remained intact, indicating that it exhibits excellent physiological stability in aqueous media.

[0061] Application Example 1: Removal of chylomicrons Untreated chylous blood samples, such as Figure 3 As shown. The composite aerogel powder prepared in Example 1 was added to the chylous lipemia sample at a mass-to-volume ratio of 300 (mg): 1 (mL). The mixture was vortexed for 1 min to ensure sufficient contact between the composite aerogel powder and the chylomicrons in the lipemia sample. After mixing, the sample was centrifuged at 3650 r / min for 10 min. The centrifuged chylous lipemia sample is shown below. Figure 4 As shown.

[0062] Depend on Figures 3-4 It can be seen that after adding composite aerogel to the turbid chylous blood sample, the chylomicrons were successfully adsorbed by the composite aerogel and precipitated at the bottom of the centrifuge tube; the supernatant was collected to obtain a clear serum sample.

[0063] The collected supernatant (clarified serum sample) was analyzed using a Siemens Attellica CH930 fully automated biochemical analyzer to detect the levels of triglycerides and total cholesterol. An untreated chylous blood sample served as a blank control group. The results are shown in Tables 2-4. Table 2 shows the adsorption of chylomicrons in the chylous blood sample by the composite aerogel; Table 3 shows the chylomicron removal rate of the composite aerogel; and Table 4 shows the effect of the composite aerogel on other non-chylomicron indicators in the chylous blood sample.

[0064] Table 2. Adsorption of chylomicrons in chylous blood samples by composite aerogel

[0065] Table 3. Clearance rate of chylomicrons in chylous blood samples by composite aerogel

[0066] Table 4. Effects of composite aerogel on other detection indicators (non-chylomicrons) in chylous blood samples

[0067] As shown in Tables 2-4, the composite aerogel prepared in Example 1 achieved a clearance rate of up to 95.69% for triglycerides, the main component of chylomicrons, and an clearance rate of 83.52% for total cholesterol, with a clearance rate of up to 95.25% for very low-density lipoprotein cholesterol. More importantly, the composite aerogel only adsorbs chylomicrons in blood samples and does not significantly interfere with other detection items such as alanine aminotransferase, total protein, potassium, and sodium (although the detection values ​​of the clarified serum samples after the addition of the composite aerogel changed, they were all within the clinically acceptable reference range or the normal fluctuation range of the detection system), with a retention rate of more than 98% for albumin.

[0068] The above results demonstrate that the heparinized silica-based composite aerogel exhibits excellent selectivity, effectively adsorbing chylomicrons in blood samples while having minimal impact on other detection parameters, thus significantly improving detection sensitivity.

[0069] Comparative Example 1: The above-mentioned chylous lipemia samples were subjected to chylomicron adsorption experiments using commercially available silica aerogel products (without heparinization modification). The specific parameters of the silica aerogel products are shown in Table 5. Table 5. Specific parameters of silica aerogel products

[0070] The adsorption experiment was performed as follows: Aerogel product 1 and aerogel product 2 were added to the chylous blood sample at a mass-to-volume ratio of 300 (mg): 1 (mL), vortexed for 1 min, and then centrifuged at 3650 r / min for 10 min. The centrifuged chylous blood sample is shown below. Figure 5 As shown in the figure, the left side of the figure shows the treatment effect of aerogel product 1 on chylous lipemia samples, and the right side shows the treatment effect of aerogel product 2 on chylous lipemia samples.

[0071] Depend on Figure 5 It can be seen that aerogel product 1 has an insignificant effect on removing chylomicrons, and the supernatant liquid after centrifugation is still turbid, making it difficult to extract serum for testing; aerogel product 2, due to its low density, has aerogel powder floating on the top layer of the chylomicron blood sample and cannot adsorb chylomicrons.

[0072] In summary, this invention provides a heparinized silica-based composite aerogel material with an extremely high specific surface area (759.5759 m²). 2 Suitable mesopore size (10~50nm) and suitable density (1.19~1.21g / cm³) 3The synergistic effect of heparin and other agents endows the material with extremely high oil absorption capacity (265 mL / g); in addition, heparin modification provides strong affinity sites for the composite aerogel, which can achieve specific adsorption by utilizing the bioaffinity of heparin. Therefore, when processing chylomicrons in blood samples, this composite aerogel material can efficiently remove oily impurities through physical adsorption while also specifically capturing target biomolecules by utilizing the bioaffinity of heparin. It can achieve near-complete chyle removal in a very short time without interfering with other detection indicators, thus solving a long-standing technical problem in current clinical testing.

Claims

1. A product for removing chylomicrons from in vitro blood samples, characterized in that, Including silica-based composite aerogels.

2. The product as described in claim 1, characterized in that, The product in question is a reagent kit.

3. The product as described in claim 1, characterized in that, The silica-based composite aerogel is a heparinized silica-based composite aerogel, and heparin molecules are grafted onto the surface of the composite aerogel.

4. The product as described in claim 3, characterized in that, The heparinized silica-based composite aerogel has a particle size of 20-50 μm, an oil absorption value of 200-300 mL / g, and a density of 1.19-1.21 g / cm³. 3 .

5. The product as described in claim 3, characterized in that, The preparation method of the heparinized silica-based composite aerogel includes the following steps: (1) Mix alkoxysilane precursor, water and alcohol solvent, then use an acid catalyst to adjust the pH of the system to 3~5, stir at 20~50℃ for 0.5~4h to carry out catalytic hydrolysis, and obtain silica sol; (2) Add an alkaline catalyst to the silica sol in step (1) to adjust the pH of the system to 8-10, stir evenly and let stand so that it gels within 10-60 min, and then age at 40-70℃ for 6-48 h to obtain wet gel. (3) Immerse the wet gel from step (2) in an ethanol solution containing sodium heparin and silane coupling agent, and react at 30~60℃ for 12~72h under sealed conditions to obtain the modified gel. In the ethanol solution, the volume ratio of ethanol is 96%~98%, the concentration of heparin sodium is 0.1~5 mg / mL, and the concentration of silane coupling agent is 1~50 mg / mL; the silane coupling agent is 3-aminopropyltriethoxysilane. (4) The modified gel in step (3) is rinsed with anhydrous ethanol 2-3 times, and then immersed in various low surface tension solvents for displacement, each displacement lasting 6-12 hours. Then, it is dried under gradient atmospheric pressure to obtain heparinized silica-based composite aerogel.

6. The product as described in claim 5, characterized in that, The alkoxysilane precursor in step (1) is tetraethyl orthosilicate, the alcohol solvent is ethanol, and the acid catalyst is one of hydrochloric acid, acetic acid, and citric acid.

7. The product as described in claim 5, characterized in that, The alkaline catalyst mentioned in step (2) is ammonia or organic amine.

8. The use of the product according to any one of claims 1 to 7 in the removal of chylomicrons from in vitro blood samples.

9. The application as described in claim 8, characterized in that, The application method is as follows: Mix the silica-based composite aerogel with the blood sample to be treated at a mass-to-volume ratio of 100~300 (mg): 1 (mL), shake at room temperature for 1~5 min, and then centrifuge at 3000~4000 r / min for 8~12 min.

10. The application as described in claim 8, characterized in that, The blood sample is serum or plasma.

Citation Information

Patent Citations

  • Flexible hydrophobic block silica aerogel and preparation method thereof

    CN113461020A

  • Hydrophobic oleophylic flexible silicon dioxide aerogel as well as preparation method and application thereof

    CN114394600A